Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Dabrafenib”

138 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 138 results

Testing effectiveness (Phase 2)Ended earlyNCT04310397
What this trial is testing

Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma

Who this might be right for
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIIC Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8
M.D. Anderson Cancer Center 4
Testing effectiveness (Phase 2)Looking for participantsNCT05525273
What this trial is testing

Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma

Who this might be right for
Craniopharyngioma
Eva Marie Erfurth, MD, PhD 25
Testing effectiveness (Phase 2)Study completedNCT01682213
What this trial is testing

Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation

Who this might be right for
Melanoma
Memorial Sloan Kettering Cancer Center 23
Testing effectiveness (Phase 2)Ended earlyNCT03391050
What this trial is testing

APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma

Who this might be right for
Melanoma
Aprea Therapeutics 3
Early research (Phase 1)Study completedNCT01738451
What this trial is testing

Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors

Who this might be right for
Cancer
GlaxoSmithKline 50
Early research (Phase 1)Ended earlyNCT03332589
What this trial is testing

E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)

Who this might be right for
Malignant MelanomaBrain Metastases
Spirita Oncology, LLC 4
Post-approval studies (Phase 4)Looking for participantsNCT03340506
What this trial is testing

Dabrafenib and/or Trametinib Rollover Study

Who this might be right for
MelanomaNon Small Cell Lung CancerSolid Tumor+2 more
Novartis Pharmaceuticals 100
Testing effectiveness (Phase 2)UnknownNCT03808441
What this trial is testing

CAcTUS - Circulating Tumour DNA Guided Switch

Who this might be right for
Melanoma
The Christie NHS Foundation Trust 21
Early research (Phase 1)Study completedNCT01340846
What this trial is testing

A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

Who this might be right for
Cancer
GlaxoSmithKline 48
Testing effectiveness (Phase 2)UnknownNCT05876806
What this trial is testing

Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations

Who this might be right for
Cancer
Se Jun Park 30
Not applicableStudy completedNCT03944356
What this trial is testing

BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients

Who this might be right for
Melanoma
EuMelaReg gGmbH 232
Testing effectiveness (Phase 2)Looking for participantsNCT06712875
What this trial is testing

MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

Who this might be right for
Low Grade GliomaHigh Grade Glioma
Ann & Robert H Lurie Children's Hospital of Chicago 27
Testing effectiveness (Phase 2)Ended earlyNCT01701037
What this trial is testing

Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery

Who this might be right for
Recurrent MelanomaStage IIB Melanoma (Locally Advanced)Stage IIC Melanoma (Locally Advanced)+4 more
Vanderbilt-Ingram Cancer Center 13
Testing effectiveness (Phase 2)Study completedNCT02684058
What this trial is testing

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Who this might be right for
Diffuse AstrocytomaAnaplastic AstrocytomaAstrocytoma+19 more
Novartis Pharmaceuticals 151
Not applicableStudy completedNCT04547946
What this trial is testing

Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)

Who this might be right for
Malignant Melanoma
Novartis Pharmaceuticals 3
Large-scale testing (Phase 3)Not Yet RecruitingNCT07440290
What this trial is testing

DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

Who this might be right for
Haematological MalignancyMalignant NeoplasmLymphoproliferative Disorders+16 more
Cancer Research UK 30
Testing effectiveness (Phase 2)Study completedNCT01336634
What this trial is testing

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

Who this might be right for
Cancer
Novartis Pharmaceuticals 177
Not applicableLooking for participantsNCT06262919
What this trial is testing

Special Drug Use-results Surveillance of Tafinlar/Mekinist

Who this might be right for
BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
Novartis Pharmaceuticals 110
Early research (Phase 1)Study completedNCT01262963
What this trial is testing

An Absorption, Distribution, Metabolism and Excretion (ADME) Study of Single Oral Dose [14C] GSK2118436 in Subjects With BRAF Mutant Solid Tumors

Who this might be right for
Cancer
GlaxoSmithKline 4
Testing effectiveness (Phase 2)Looking for participantsNCT07506109
What this trial is testing

A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

Who this might be right for
BRAF V600EColorectal CancerSintilimab+4 more
Tianjin Medical University Cancer Institute and Hospital 49
Load More Results